zanubrutinib (Brukinsa) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
BGB-3111 is a potent and highly selective small molecule BTK inhibitor (Bruton’s Tyrosine Kinase), which we are developing as a monotherapy and in combination with other therapies for the treatment of a variety of lymphomas—the most common form of blood cancer. BGB-3111 blocks the signaling that leads to growth inhibition and cell death in malignant B-cells. In preclinical studies, BGB-3111 showed more restricted off-target activities against a panel of kinases, including ITK. Due to the weaker activity on ITK, BGB-3111 was at least 10 times weaker than ibrutinib in inhibiting rituximab-induced ADCC activity. Both in the REC-1 MCL and ABC subtype DLBCL (TMD-8) xenograft models, BGB-3111 induced dose-dependent antitumor effects and demonstrated superior efficacy in comparison with ibrutinib. Toxicity study in rats indicated that BGB-3111 was very well tolerated, and the MTD was not reached when it was dosed up to 250 mg/ kg/day. The first-in-human, open-label phase 1 trial of BGB-3111 is ongoing as a modified 3 + 3 dose-escalation design (40, 80, 160, 320 mg PO QD; 160 mg PO BID) in patients with advanced B cell malignancies.   NCATS

  • SMILES: NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4
  • InChIKey: RNOAOAWBMHREKO-QFIPXVFZSA-N
  • Mol. Mass: 471.5509
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Drug Pricing (per unit)

United States

$78.1614 - $99.4500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue